An initial study found that IFN-λ2 did not significantly modulate GVHD mortality in a murine model upon deleting its receptor (Ifnlr1-/-) or administration of recombinant IFN-λ2 (82). This evidence concerns the gene IFNLR1 and graft versus host disease.